“A new class of experimental cholesterol drugs might sharply reduce the risk of heart attacks and strokes, researchers reported on Sunday, citing what they described as preliminary evidence,” The New York Times reports today.
The full story here:
mobile.nytimes.com/2015/03/16/bu … rrer=&_r=0
And this is why I love it:
(1) The lead investigator is Dr. Marc S. Sabatine… of Brigham and Women’s Hospital (which, in case you’re not aware, is a teaching affiliate of Harvard Medical School), and
(2) The manufacturers of the drugs are (drumroll, please)… Amgen, Sanofi and Regeneron. Which is to say Merck had no part of this pharmaceutical venture.
So let’s all have a big hand for Amgen, Sanofi and Regeneron, and the work they have done at Brigham and Women’s Hospital (a teaching affiliate of, well, you know).
Oh, and, as the late great Steve Jobs used to say, one more thing: the studies were published in The New England Journal of Medicine.
A big goddamn hand, ladies and gentlemen, a BIG goddamn hand.
And after you’re finished, let’s use it to slap you-know-who 'cross his natural you-know-what-color ass.